Modulation of gastric emptying as a therapeutic approach to glycaemic control

Diabetic Medicine

Volumn 13, Issue SUPPL. 5, 1996, Pages

  Moyses, C ^a   Young, A ^b   Kolterman, O ^b  

^a Amylin Europe Ltd   (United Kingdom)

^b AMYLIN PHARMACEUTICALS INC   (United States)

Author keywords

Amylin; Diabetes mellitus; Gastric emptying; Glucagon; Glycaemic control; Pramlintide

Indexed keywords

AMYLIN; GLUCAGON; GLUCOSE; PRAMLINTIDE;

CONFERENCE PAPER; DIABETES MELLITUS; GLUCAGON RELEASE; GLUCOSE HOMEOSTASIS; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; STOMACH EMPTYING;

AMINO ACID SEQUENCE; AMYLOID; ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; GASTRIC EMPTYING; GLUCAGON; HUMANS; HYPERGLYCEMIA; MOLECULAR SEQUENCE DATA; POSTPRANDIAL PERIOD; RATS;

EID: 0029818013     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Horowitz M, Fraser R. Disordered gastric motor function in diabetes mellitus. Diabetologia 1994; 37: 543-551.
2. Kong M-FS-C, Macdonald IA, Tattersall RB. Gastric emptying in diabetes. Diabetic Med 1996; 13: 112-119.
3. Cooper GJS, Willis AC, Clark A, Turner RC, Sim RB, Reid KB. Purification and characterization of a peptide from amyloid-rich pancreas of Type 2 diabetic patients. Proc Natl Acad Sci USA 1987; 84: 8628-8632.
4. Cooper GJS, Leighton B, Dimitriadis GD, et al. Amylin found in amyloid deposits in human Type 2 diabetes mellitis may be a hormone that regulates glycogen metabolism in skeletal muscle. Proc Natl Acad Sci USA 1988; 85: 7763-7766.
5. Ogawa A, Harris V, McCorkle SK, Unger RH, Luskey KL. Amylin secretion from rat pancreas and its selective loss after streptozotocin treatment. J Clin Invest 1990; 85: 973-976.
6. Castillo MJ, Scheen AJ, Lefebvre PJ. Amylin/islet amyloid polypeptide: biochemistry, physiology, patho-physiology. Diabete Metab 1995; 21: 3-25.
7. Koda JE, Fineman MS, Kolterman OG, Caro JF. 24 hour plasma amylin levels are elevated in IGT subjects vs. normal controls. Diabetes 1995; 44 (suppl 1): 238A.
8. Janes S, Gaeta L, Beaumont K, Beeley N, Rink T. The selection of pramlintide for clinical evaluation. Diabetes 1996; 45 (Suppl 2): A865.
9. Koda JE, Fineman M, Rink TJ, Dailey GE, Muchmore DB, Linarelli LG. Amylin concentrations and glucose control. Lancet 1992; 339: 1179-1180.
10. Data on File.
11. Kolterman OG, Gottlieb AB, Moyses C, Colburn W. Reduction of postprandial hyperglycaemia in subjects with IDDM by intravenous infusion of AC137, a human amylin analogue. Diabetes Care 1995; 18: 1179-1182.
12. Kolterman O, Organ K, Gottlieb AB. Intravenous infusion of the human amylin analog, AC 137, reduces postprandial hyperglycemia in subjects with Type 1 diabetes mellitus receiving oral nutrients but not intravenous glucose. Diabetes 1995; 44 (suppl 1): 57A.
13. Thompson RG, Gottlieb AB, Organ K, Kolterman OG. The human amylin analog (AC137) reduces glucose following Sustacal® in patients with Type II diabetes. Diabetes 1995; 44 (suppl 1): 127A.
14. Young AA, Gedulin B, Vine W, Percy A, Ring TJ. Gastric emptying is accelerated in diabetic BB rats and is slowed by subcutaneous injections of amylin. Diabetologia 1994; 38: 642-648.
15. Gedulin BR, Jodka CM, Green DE, Young AA. Potency and effectiveness of amylin and five gut peptides on gastric emptying in rats. Diabetes 1995; 44 (suppl 1): 133A.
16. Macdonald I, King P, Kong M-F, Stubbs T, Perkins A, Moyses C, Tattersall R. Infusion of the human amylin analogue, AC137, delays gastric emptying in men with IDDM. Diabetologia 1995; 38 (suppl 1): A32.
17. Young A, Gedulin B, Jodka C, Green D. Insulin-induced hypoglycaemia reverses amylin-inhibifion of gastric emptying in rats. Diabetes 1996; 45 (Suppl 2): A689.
18. Young AA, Jodka CM, Green BE, Gedulin BR. Inhibition of arginine-induced glucagon secretion of amylin in rats. Diabetes 1995; 44 (suppl 1): 238A.
19. Thompson RG, Gottlieb AB, Peterson J. The human amylin analogue AC137 reduces mean 24 hour glucose in Type 1 diabetes. Diabetologia 1995; 38 (suppl 1): A44.